Seer, Inc. confirmed receipt of two revised, non-binding acquisition proposals to acquire all outstanding Class A common shares. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right (CVR). On July 29, 2026, CEO Omid Farokhzad submitted a revised proposal offering $2.45 per share in cash plus two CVRs, potentially delivering up to $7.69 per share if revenue and sale milestones are met. The Special Committee will review these offers alongside other alternatives. Seer, Inc. operates in the biotechnology industry, providing deep proteomic insights through its Proteograph product suite.
